Background: Efavirenz and lopinavir boosted with ritonavir are both recommended as first-line therapies for patients with HIV when combined with two nucleoside reverse transcriptase inhibitors. It is uncertain which therapy is more effective for patients starting therapy with an advanced infection. Methods: We estimated the relative effect of these two therapies on rates of virological and immunological failure within the Swiss HIV Cohort Study and considered whether estimates depended on the CD4 + T-cell count when starting therapy. We defined virological failure as either an incomplete virological response or viral rebound after viral suppression and immunological failure as failure to achieve an expected CD4 + T-cell increase calculated from EuroSIDA statistics. Results: Patients starting efavirenz (n=660) and lopinavir (n=541) were followed for a median of 4.5 and 3.1 years, respectively. Virological failure was less likely for patients on efavirenz, with the adjusted hazard ratio (95% confidence interval) of 0.63 (0.50-0.78) then multiplied by a factor of 1.00 (0.90-1.12) for each 100 cells/mm 3 decrease in CD4 + T-cell count below the mean when starting therapy. Immunological failure was also less likely for patients on efavirenz, with the adjusted hazard ratio of 0.68 (0.51-0.91) then multiplied by a factor of 1.29 (1.14-1.46) for each 100 cells/ mm 3 decrease in CD4 + T-cell count below the mean when starting therapy. Conclusions: Virological failure is less likely with efavirenz regardless of the CD4 + T-cell count when starting therapy. Immunological failure is also less likely with efavirenz; however, this advantage disappears if patients start therapy with a low CD4 + T-cell count.
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As a first-line therapy for patients with HIV, guidelines recommend either a boosted protease inhibitor (PI) or efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), together with two nucleoside reverse transcriptase inhibitors (NRTIs) [1] . Lopinavir boosted with low-dose ritonavir (LPV/r) is a common choice of boosted PI for first-line therapy. A number of randomized trials and longitudinal cohort studies compare these two therapies in treatment-naive patients [2] [3] [4] [5] [6] [7] [8] [9] . The only large randomized trial to date (ACTG 5142) shows that virological failure is less likely with EFV-based therapy; however, LPV/r-based therapy leads
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Introduction to greater increases in CD4 + T-cell count [2] . Authors of other studies have either come to the same conclusions or report no differences between the two therapies; however, these other studies may lack the power to detect the differences seen in a large trial.
It is uncertain whether these conclusions apply to patients starting therapy with an advanced infection [10] . Results from a recent small randomized trial suggest that patients with a low CD4 + T-cell count are more likely to achieve an undetectable viral load with EFV [4] ; however, results from a larger cohort of patients with a low CD4 + T-cell count suggest that both therapies have a similar risk of virological failure [9] . In trial ACTG 5142, virological failure was less likely with EFV only in patients with a baseline viral load of ≥100,000 copies/ml [2] and there was no difference between the two therapies in patients with a baseline CD4 + T-cell count <100 cells/mm 3 [11] . In this study, we use data from the Swiss HIV Cohort Study (SHCS) to compare virological and immunological responses to first-line therapy with either EFV or LPV/r, and to consider whether these responses depend on the CD4 + T-cell count when starting therapy. To reduce the variability of our data, we restricted our analyses to patients starting either EFV or LPV/r and the same two NRTIs: lamivudine (3TC) and zidovudine (AZT).
Methods
Patients
The SHCS is a prospective cohort with continuing enrolment of HIV-infected adults. Our population of interest included all antiretroviral-naive patients starting first-line therapy with either EFV or LPV/r and with the NRTI backbone 3TC and AZT. Our sample included all patients from this population with plasma HIV RNA (viral load) and CD4 + T-cell count measured between 6 months before and 3 months after starting therapy. Viral load and CD4 + T-cell count were measured at follow-up visits scheduled 6 months apart, but measurements were also made in between official cohort visits and stored in the SHCS database. We followed these patients until their last recorded measurement to date, although in two different 'as treated' analyses, we either censored measurements after a patient started or stopped any PI or NNRTI, or censored measurements after a patient started or stopped any component of antiretroviral therapy.
Events of interest
Our definition of virological failure follows recommendations in the US Department of Health and Human Services guidelines for the use of antiretroviral agents [12] . We defined virological failure as either an incomplete virological response (the first of two consecutive viral load measurements >400 copies/ml after 24 weeks or >50 copies/ml after 48 weeks) or viral rebound after viral suppression (the first of two consecutive detectable viral load measurements after two consecutive undetectable viral load measurements).
Immunological failure is the failure to achieve an adequate CD4 + T-cell response despite viral suppression, although there is no recommended definition [12] . We defined immunological failure as the failure to achieve an expected rate of CD4 + T-cell increase calculated from EuroSIDA statistics. These statistics give an expected rate of CD4 + T-cell increase for patients with viral suppression depending on the CD4 + T-cell count when starting therapy and on the number of years since starting therapy after adjusting for age, therapy, time taken to achieve viral suppression and change in CD4 + T-cell count since starting therapy (see Table 3 in [13] ). From the tabled means and confidence intervals (CIs) [13] , we calculated a minimum rate of CD4 + T-cell increase that at least 80% of patients should achieve (this led to a decrease in CD4 + T-cell count that should not be exceeded; Additional file 2, Appendix 1); we defined immunological failure as the first of two consecutive measurements where this minimum increase was not achieved; and we did not censor patients if they experienced virological failure. The 80% threshold was arbitrarily set to provide a similar number of failures as our definition of virological failure.
Time-to-event analyses
We fitted Cox proportional hazard models to these data using pooled logistic regression with each person-month as an observation [14] . Provided the probability of an event in any one person-month is low, this is equivalent to fitting a time-dependent Cox proportional hazards model [15] . This method of model fitting allows the use of inverse probability weights for confounder control, so that covariates can be added only as needed for effect modification [16] . The inverse probability weights we used for confounder control (Additional file 2, Appendix 2) were calculated from variables that have been used as covariates in similar cohort studies (gender, likely mode of transmission and at baseline, advanced HIV infection, chronic hepatitis B infection, hepatitis C infection, age, viral load, CD4 + T-cell count and number of years since the first use of EFV [7, 8] ).
A key question for this study is whether the relative benefits of therapy depend on a patient's CD4 + T-cell count when starting therapy. To answer this question, we added covariates to our models for baseline CD4 + T-cell count and for the interaction between baseline CD4 + T-cell count and therapy, and then reported a CI for the interaction. The estimate for this interaction shows how the benefit of one therapy relative to First-line therapy for patients with HIV the other is modified by the CD4 + T-cell count when starting therapy. We centred baseline CD4 + T-cell count and other continuous covariates around their means to minimize the correlation between an interaction and its components [17] .
We also report results for a series of sensitivity analyses. First, we restricted our data to patients starting therapy after 15 January 2001 when LPV/r became widely available with the cost of its use covered by Switzerland's compulsory health insurance (Additional file 2, Appendix 3). Second, we added prior information to our analyses (Additional file 2, Appendix 4) -this can be particularly helpful when estimating unstable model coefficients, such as interaction terms. Third, we considered virological and immunological events that have been analysed in other studies (Additional file 2, Appendix 5).
For each analysis, we report a hazard ratio (HR) for the relative effect of therapy and its 95% CI. All ratios used LPV/r as the reference therapy. We used SAS version 9.1.3 (SAS Institute Inc., Cary, NC, USA) for analyses and R version 2.5.1 (R Foundation for Statistical Computing, Vienna, Austria) for graphics.
Results
Patient characteristics
As of 24 July 2008, 1,338 patients in the SHCS had started first-line therapy with the two NRTIs, 3TC and AZT, and either EFV or LPV/r. Of these, 1,201 (90%) patients had viral loads and CD4 + T-cell counts measured between 6 months before and 3 months after starting therapy. Patients starting LPV/r were likely to start therapy at an early clinical stage of infection, but with higher viral load and lower CD4 + T-cell count than those starting EFV (Table 1 ). These 1,201 patients had been followed for a total of 4,600 person-years, with a median follow-up of 4.5 and 3.1 years for patients starting EFV and LPV/r, respectively. During this time, 13,700 viral load measurements had been made, with a median time between measurements of 3.0 months (interquartile range [IQR] 2.3-3.8) and 2.6 months (IQR 1.6-3.1) for patients starting EFV and LPV/r, respectively.
Changes to therapy
Changes to first-line therapy were common, with only 214 (18%) of the 1,201 patients still on their first-line therapy at the end of follow-up ( Table 2 ). The first modification to therapy was usually a change to the PI or NNRTI component (58%) rather than a change to the NRTI backbone (24%). Changes to the NRTI backbone were made earlier with LPV/r-based therapy (median 4 months) than with EFV-based therapy (median 23 months). Treatment interruptions were common for patients on both therapies, but patients starting EFV were more likely to switch to an all NRTI-based therapy. Many patients on both therapies switched to antiretrovirals associated with a lower risk of metabolic abnormalities (such as abacavir, tenofovir and atazanavir).
Virological failure
In 'intent-to-treat' analyses (that is, without censoring patients if they change therapy), 234 (35%) of 660 patients starting EFV experienced virological failure with a median time to failure of 17 months; 192 (35%) of 541 patients starting LPV/r experienced virological failure with a median time to failure of 16 months. Virological failure was less likely for patients starting first-line therapy with EFV -although a similar proportion of patients failed with each therapy, on average, patients starting EFV had been followed for longer (Figure 1 ). The unadjusted HR (95% CI) for the relative effect of therapy was 0.77 (0.63-0.93), the HR adjusted Table 2 . First change to therapy and median time to this change for treatment-naive patients starting therapy with either EFV or LPV/r plus 3TC and AZT a Time (in months) from starting therapy to the first change in therapy. ABC, abacavir; ATV/r, atazanavir boosted with ritonavir; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; LPV/r, lopinavir boosted with low-dose ritonavir; NFV, nelfinavir; NVP, nevirapine; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine. using inverse probability weights was 0.64 (0.51-0.80) and the HR adjusted using the usual set of baseline covariates was 0.57 (0.46-0.72; Table 3 ).
Adding baseline CD4 + T-cell count and its interaction with therapy to the model gave an HR (95% CI) for therapy of 0.63 (0.50-0.78) and the interaction term showed that for each 100 cells/mm 3 decrease in baseline CD4 + T-cell count below the mean, this HR was then multiplied by a factor of 1.00 (0.90-1.12). Hence the effect of therapy on the risk of virological failure was independent of the CD4 + T-cell count when starting therapy. There was also no clear evidence that the effect of therapy on virological failure depended on the viral load when starting therapy (Additional file 2, Appendix 5).
In 'as treated' analyses adjusted using inverse probability weights, the HR (95% CI) for therapy was 0.54 (0.36-0.82) when patients were censored after starting or stopping any PI or NNRTI, and 0.56 (0.36-0.87) when patients were censored after starting or stopping any component of therapy.
Immunological failure
In 'intent-to-treat' analyses, 127 (19%) of 660 patients starting EFV failed to achieve the expected increase in CD4 + T-cell count with a median time to failure of 30 months; 125 (23%) of 541 patients starting LPV/r failed to achieve the expected increase with a median time to failure of 13 months. The unadjusted HR (95% CI) for the relative effect of therapy was 0.57 (0.44-0.73), the HR adjusted using inverse probability weights was 0.67 (0.50-0.88) and the HR adjusted using the usual set of covariates was 0.62 (0.47-0.82; Table 3 ).
These estimates of the relative effect of therapy suggested that immunological failure was less likely if patients started first-line therapy with EFV; however, adding baseline CD4 + T-cell count and its interaction with therapy to the model gave an HR for therapy of 0.68 (0.51-0.91) and the interaction term showed that for each 100 cells/mm 3 decrease in baseline CD4 + T-cell count below the mean, this HR was then multiplied by a factor of 1.29 (1.14-1.46). Hence, the effect of therapy on the risk of immunological failure was dependent on the CD4 + T-cell count when starting therapy: patients on EFV had a lower risk of failing to achieve the expected rate of CD4 + T-cell increase unless they started therapy with a low CD4 + T-cell count. Figure 2 is consistent with this result: patients who started therapy with a CD4 + T-cell count ≤200 cells/mm 3 appeared to have a better response on average if their first-line therapy was LPV/r rather than EFV.
We fitted this interaction model in two 'as treated' analyses, each adjusted using inverse probability weights. When patients were censored after starting or stopping any PI or NNRTI, the HR (95% CI) for therapy was 0.49 (0.33-0.73) multiplied by a factor of 1.16 (0.97-1.39) for each 100 cells/mm 3 decrease in baseline CD4 + T-cell count below the mean. When
Each estimate is a hazard ratio (HR) and its 95% confidence interval (CI) with lopinavir boosted with low-dose ritonavir (LPV/r) as the reference therapy. a Both sets refer to both point treatment and time-dependent weights (Additional file 2, Appendix 2).
b Full set refers to gender, likely mode of transmission and, at baseline, advanced HIV infection (CDC group C), chronic hepatitis B infection, hepatitis C infection, age, viral load, CD4 + T-cell count and number of years since 1998. Interaction with baseline marker refers to a marker at baseline and its interaction with therapy. AZT, zidovudine; EFV, efavirenz; NNRTI, non-nuceloside reverse transcriptase inhibitor; PI, protease inhibitor; 3TC, lamivudine. 
Discussion
Our results suggest that virological failure is a less likely outcome for patients starting first-line therapy with EFV, regardless of their CD4 + T-cell count when starting therapy. Immunological failure also appears to be less likely for patients starting first-line therapy with EFV, unless patients start therapy with a low CD4 + T-cell count. Therefore, our results appear to both confirm and contradict results from the only large randomized trial (ACTG 5142) where these two therapies have been compared [2] .
In trial ACTG 5142, virological failure was less likely for patients on EFV with a similar HR to that reported here [2] . Previous cohort studies have not reported a clear advantage for patients on EFV and our sensitivity analyses suggest that this is because these studies did not follow patients for a sufficient period of time (Additional file 2, Appendix 5). In this study, median follow-up was 4.5 and 3.1 years for patients starting EFV and LPV/r, respectively. By contrast, the median follow-up was 2.2 years in trial ACTG 5142 [2] and the mean follow-up was 1.5 and 0.8 years, respectively, in two previous cohort studies [7, 8] .
In trial ACTG 5142, greater increases in baseline CD4 + T-cell count were seen in patients starting therapy with LPV/r [2] . Our results suggest that patients starting EFV are more likely to achieve expected CD4 + T-cell increases; however, this advantage disappears if patients start therapy with a low CD4 + T-cell count. Patients in our study started therapy with higher CD4 + T-cell counts (median 270 and 220 cells/mm 3 for patients starting EFV and LPV/r, respectively) than patients in ACTG 5142 (median 190 cells/mm 3 ) and this difference may have contributed to these apparent contradictory results. The longer median follow-up in our study may have also contributed to these apparent contradictory results: if EFV is less likely to lead to virological failure, in time this must represent an advantage for immune recovery as well because immune recovery improves if patients maintain viral suppression [18] . The average response curves shown are those calculated by the default LOESS function in R version 2.5.1 [37] . Response curves are shown for patients starting therapy with a CD4 + T-cell count either (A) ≤200 cells/mm 3 or (B) >200 cells/mm 3 . Note that the two response curves for efavirenz (EFV) are very similar, whereas the two response curves for lopinavir boosted with low-dose ritonavir (LPV/r) are quite different. AZT, zidovudine; 3TC, lamivudine.
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Previous cohort studies have not shown a clear advantage for immune recovery of one therapy over the other in the short term; however, the immune events used in these studies occur relatively quickly for most patients (Additional file 2, Appendix 5) and so these events are not well suited to evaluating the medium term (3-5 years) consequences of therapy for immune recovery. The immune event we use here -the expected CD4 + T-cell increase based on EuroSIDA statistics for patients with viral suppression -shows promise as results for this event are consistent with changes seen in the CD4 + T-cell count over time. These expected CD4 + T-cell increases were calculated from patients with viral suppression, but such increases are still desirable treatment goals for patients with a detectable viral load. In our analyses of this event, we did not censor patients when they experienced virological failure. Hence, our estimates show the overall effect of therapy on immune recovery (where virological failure may have contributed to that overall effect) rather than the effect of therapy on immune recovery in patients with viral suppression.
Contradictory subgroup results have been reported in previous comparisons of these two therapies (Additional file 2, Appendix 5). Randomized trials typically have sufficient power to detect relevant differences between the randomized groups, but not between subgroups [19, 20] , and cohort studies may be no more powerful even if they include more patients because the data they use are inherently more variable. In order to demonstrate subgroup differences, investigators should add interaction terms to analytical models without categorizing continuous covariates and report CIs for these interactions [21] [22] [23] . Our estimates for interaction terms are only moderately precise, yet only those who are very sceptical about an interaction between baseline CD4 + T-cell count and therapy (with prior HR 1.00 [95% CI 0.91-1.09]) would not be convinced by these data that the relative benefit of therapy for immune recovery depends on a patient's CD4 + T-cell count when starting therapy (Additional file 2, Appendix 4).
Because our estimates are only moderately precise, we did not attempt to estimate the relative effect of therapy in each of several categories of baseline CD4 + T-cell count. To illustrate this lack of precision, therapy and interaction effects implied that the two therapies had the same risk of immunological failure for patients with a baseline CD4 + T-cell count of 90 cells/mm 3 , but an approximate 95% CI for this estimate (found using the delta method) was from below 0 (-50) to 240 cells/mm 3 . Even then, this estimate is only a rough guide because our model for the interaction between the effect of therapy and baseline CD4 + T-cell count assumes the interaction has a linear effect on the log hazard function and this approximation could be unreliable at low and high baseline CD4 + T-cell counts. In short, although our results indicate that EFV loses its advantage for immune recovery if patients start therapy with a low CD4 + T-cell count, more definitive conclusions are not possible with these data.
We restricted our analyses to two specific first-line therapies with the same NRTI backbone of 3TC and AZT because this strategy leads to more precise estimates (Additional file 2, Appendix 5). Although the preferred backbone is now emtricitabine and tenofovir [12] , and 3TC and abacavir give greater CD4 + T-cell increases than 3TC and AZT [24] , restricting the analysis to a single backbone would not affect our conclusions unless the relative (rather than absolute) effects of these two therapies differ between backbones. To date, there are no known interactions of clinical relevance between the various backbones and either EFV or LPV/r (see Table 15c in [12] ).
In 'as treated' analyses, confounder control by inverse probability weights offers an obvious advantage because many changes to therapy are likely to be informative. For example, patients responding well to therapy may switch from their first-line therapy to an all NRTI-based therapy or patients responding poorly may switch either from an NNRTI to a PI or the reverse. In this study, 'as treated' estimates, adjusted using inverse probability weights, were always at least as far from the null (a hazard ratio of one) as 'intent-to-treat' estimates -as one would expect if one therapy is actually more potent than another [25] . Hence, 'as treated' estimates suggest that the advantages of EFV seen in 'intent-to-treat' analyses do not arise because of changes to the first-line therapy, which are common and often rapid, but rather reflect an underlying superior potency.
Unfortunately 'as treated' estimates are not reliable measures of the relative intrinsic potency of therapy because adherence may differ between therapies and less than perfect adherence may have different consequences for each therapy. EFV has the lower pill burden and this may make it easier for patients to adhere to therapy [26] . By contrast, periods of nonadherence to EFV-based therapy may be more likely to lead to resistance [27] . Although the practical consequences of a physician recommending one therapy or the other are given by 'intent-to-treat' estimates, the relative merits of the two therapies under perfect adherence is relevant from a patient perspective [25] . However, to identify patients with perfect adherence requires electronic monitoring as self-reporting overestimates adherence [28] , and so the question of which therapy has the better intrinsic potency may never be fully answered.
Other important reasons for preferring one therapy over another are the risk of metabolic abnormalities and body fat changes, and the consequences of virological failure for future treatment options. Previous comparisons of these two therapies have shown that metabolic abnormalities are more common for patients starting first-line therapy with LPV/r [2, 7, 8] , with greater increases in body fat for patients on LPV/r, but lipoatrophy more common for patients on EFV [2, 29] ; however, drug-resistant mutations are more common after virological failure for patients starting first-line therapy with EFV [2] . These results are consistent with studies of metabolic abnormalities and drug resistance in our cohort [30] [31] [32] .
This study underscores two wider issues. The first issue is the need to evaluate therapies beyond the short term [33] , particularly when trying to discriminate between proven therapies, and to chose suitable events with which to assess effectiveness in the medium term. The second issue is the growing importance of assessing moderators of the effects of therapy and there is an obvious need for better planning of subgroup analyses and for the use of more appropriate statistical methods [33] [34] [35] [36] .
Our study confirms results from the only large trial to date, which show that virological failure is less likely with EFV-based therapy; however, our results suggest that this advantage does not depend on the CD4 + T-cell count or viral load when starting therapy. Again in contrast to this trial, our results suggest that expected increases in CD4 + T-cell count are more likely with EFV-based therapy; however, this depends on the CD4 + T-cell count when starting therapy so that this advantage disappears if patients start therapy with a low CD4 + T-cell count.
